YM Biosciences was founded in 1994 and is headquartered in Mississauga, Canada. YM Biosciences Inc., a biopharmaceutical company, engages in the licensing and commercialization of drug products and technologies primarily for the treatment of cancer or cancer-related conditions worldwide. Its approved product Nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor, is used for the treatment nasopharyngeal carcinomas, head and neck cancer, refractory children glioma, adult glioma, and stage III/IV glioma. The company is also developing Nimotuzumab for various other epithelial cancers; and AeroLEF, a proprietary formulation of free and liposome-encapsulated fentanyl administered by pulmonary inhalation for the treatment of severe and moderate acute pain, including cancer pain. In addition, its other product candidates include TGFa and HER-1, the anti-cancer vaccines.

Oncolytics Biotech is bringing in viral mercenaries to fight in the battle against cancer. The company is developing REOLYSIN, a therapy that utilizes a Respiratory Enteric Orphan virus (or reovirus) to treat a variety of advanced cancer tumors, both alone and in combination with other drug therapies, as well as radiation and chemotherapy. The Canadian company is collaborating with the US-based National Cancer Institute to conduct clinical trials of the treatment. It also conducts trials in Canada and the UK. Oncolytics' technologies are based on discoveries made by the Department of Microbiology and Infectious Diseases at the University of Calgary.

NextGen Group, which does business as NextGen Sciences, puts proteins to the test. The research and development company provides protein analysis services for biotechnology and pharmaceutical customers around the world. Specific services include biomarker discovery and assay development, which are often used in the drug development process to test preclinical and clinical samples for therapeutic efficacy and safety. NextGen's biomarker projects focus on Alzheimer's disease and oncology, among other therapeutic areas. The group has operations in the US and the UK.

Purdue Pharma L.P. company specializes in developing, manufacturing, and marketing sustained-release and long-acting treatments for chronic and severe pain. Its opioid drugs for pain relief include controlled-release analgesics OxyContin (a version of oxycodone), Ryzolt (tramadol), and morphine drug MS Contin. The company continues to develop and commercialize new products through alliances with such companies as Transcept and Labopharm. Purdue also sells a number of non-prescription products including topical antiseptic Betadine and the Colace and Senokot lines of laxatives. Purdue Pharma operates in the US.

Skystar Bio-pharmaceutical Company ("Skystar") is one of China's leading manufacturers and distributors of vaccines and medicines for poultry, livestock and domestic pets. Skystar has over 173 products in its current product line and has over 50 more products in development. Skystar employs over 200 people in Production Facilities located in Hu Xian, Xi'an City, Shaanxi, Province, PRC.Skystar has recently opened (July of 2006) its new GMP Certified Facility that will increase production capabilities by 200%. The demand for veterinary medicines and vaccines in China far exceeds the supply and Skystar's plan is to capitalize on its new GMP Certified Facility to increase margins while increasing production to help meet the growing and overwhelming demand for its products.

Genencor manufactures genetically modified enzymes for the industrial, agricultural, and consumer products markets. Using its biotechnology know-how, the company discovers useful enzymes (naturally occurring protein catalysts) and develops them for mass production; the enzymes are used in myriad ways, including as additives in animal feed and detergents, as a method of converting starch into ethanol, and in the production of textiles and paper. Genencor International is a division of food ingredient company Danisco.

Phase 2 Discovery partners with pharmaceutical companies to develop early-stage drug candidates that could treat various central nervous system diseases and conditions. The company also acquires drug candidates, takes them through Phase I and II clinical studies, and then offers the company the option of re-acquiring them Phase 2's goal is to speed up the discovery process for multiple compounds that could aid patients with psychiatric and neurological disorders.

Centocor Ortho Biotech has ways of making your immune system behave itself. The Johnson & Johnson subsidiary makes blockbuster biotech drug Remicade, a monoclonal antibody used to treat a number of autoimmune conditions, or diseases in which the body's immune system attacks its own tissues. It is approved in the US and Europe for several indications, including Crohn's disease, ulcerative colitis, psoriasis, rheumatoid arthritis, and ankylosing spondylitis (a type of arthritis of the spine). The company also makes oncology drugs Doxil and Leustatin, and immunosuppressant Orthoclone for organ transplantation.

Stiefel Laboratories, Inc. company's products treat a variety of dermatological ailments including acne, psoriasis, and even warts. Among the company's prescribed products are Duac and Brevoxyl acne medications and rosacea treatment Rosac. Stiefel also makes such over-the-counter remedies as fungal infection treatment Zeasorb and Sarna Lotion for itchy skin. Through subsidiaries, the company has manufacturing, marketing, and research operations in more than 30 countries, and markets it products in more than 70 countries. Founded in 1847, the company was owned by the Stiefel family before being acquired by GlaxoSmithKline in 2009.

Gilead Palo Alto (formerly CV Therapeutics) is honed in on cardiovascular research. The drug development company specializes in pharmaceuticals to treat chronic cardiovascular diseases. The firm's drug Ranexa, licensed from a Roche subsidiary, is FDA-approved as a first-line and second-line treatment for patients with chronic angina (chest pain). Gilead Palo Alto won approval for its cardiac imaging agent, Lexiscan, in 2008; the drug is marketed by Astellas Pharma. The company is developing potential therapies for ailments including heart failure and atrial fibrillation (irregular heartbeat). Gilead Palo Alto changed its name from CV Therapeutics after being acquired by Gilead Sciences in 2009.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.